Verona Pharma price target raised to $42 from $36 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $42 from $36 and keeps a Buy rating on the shares post the Q3 ...
Verona Pharma plc (NASDAQ:VRNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...
Verona Pharma to Present at Jefferies London Healthcare Conference
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...
Verona Pharma Receives Buy Rating Amid Strong Financial Performance and Growth Prospects
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...
pharmaphorum23h
Verona cuts $400m loan deal as it preps COPD drug for market
Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine ...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...
Verona Pharma Q3 2024 Earnings Preview
Verona Pharma (NASDAQ:VRNA) is scheduled to announce Q3 earnings results on Monday, November 4th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $2.01M.